New therapeutic approaches for familial amyloidotic polyneuropathy based on the amyloid formation mechanism
基于淀粉样蛋白形成机制的家族性淀粉样多发性神经病的新治疗方法
基本信息
- 批准号:17390254
- 负责人:
- 金额:$ 10.42万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2007
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
From April, 2005 to March, 2008, we performed the following therapeutic experiments for familial amyloidotic polyneuropathy, such as 1.Cr^<3+> therapy to stabilize TTR in tetrameric form, 2.inhibition of amyloid formation by BSB or FSB, 3.antibody therapy targeting for the misfolding epitope which newly expose to the outside of the TTR molecule, and 4.gene therapy using single stranded oligonucleotides(SSOs)to shut out TTR production in the liver and retina. Experimental results were the followings. 1. Administration of Cr^<3+> to the transgenic mice and rats having human ATTR V30M gene did not suppress neither amyloid nor TTR deposition. 2.We prepared amyloid scintigraphy system to detect amyloid deposition in the tissues with real time and also prepared PET system in vivo. 3.Concerning antibody therapy, we focused TTR115-124 fragment antibody to prevent amyloid formation. This epitope reacts with only amyloid fibrils, but not serum TTR. The antibody for TTR115-124 fragment suppressed TTR amyloid formation without reducing serum TTR concentrations in transgenic rat having ATTR V30M gene. 4. SSOs did convert TTR gene in the liver and retina (8% and 1%, respectively). In addition, as an treatment for the ocular amyloidosis occurring even after liver transplantation, we performed laser beam administration to the retinal pigmental cells to reduce the number of the cells, which was promising for retarding the progression of FAP.From these results, we concluded both antibody therapy and gene therapy are promising therapy as an essential therapy for FAP. In the next project, we will focus on these two research projects.
从2005年4月至2008年3月,我们对家族性淀粉样多发性神经病进行了以下治疗实验,如1. Cr ^<3+>治疗以稳定TTR四聚体形式,2. BSB或FSB抑制淀粉样蛋白形成,3.针对新暴露于TTR分子外部的错误折叠表位的抗体治疗,和4.使用单链寡核苷酸(SSO)的基因治疗以阻断肝脏和视网膜中TTR的产生。实验结果如下。1.对携带人ATTR V30 M基因的转基因小鼠和大鼠给予Cr^<3+>,既不能抑制淀粉样蛋白的沉积,也不能抑制TTR的沉积。2.制备了淀粉样蛋白成像系统,用于真实的实时检测组织中淀粉样蛋白的沉积,并制备了PET系统。3.在抗体治疗方面,我们关注TTR 115 -124片段抗体以防止淀粉样蛋白形成。该表位仅与淀粉样纤维反应,而不与血清TTR反应。TTR 115 -124片段的抗体抑制TTR淀粉样蛋白形成,而不降低具有ATTR V30 M基因的转基因大鼠中的血清TTR浓度。4. SSO确实在肝脏和视网膜中转化TTR基因(分别为8%和1%)。此外,作为肝移植后发生的眼部淀粉样变性的治疗方法,我们对视网膜色素细胞进行了激光照射,减少了色素细胞的数量,这对延缓FAP的进展是有希望的。从这些结果中,我们得出结论,抗体治疗和基因治疗作为FAP的基本治疗方法都是有希望的。在下一个项目中,我们将重点关注这两个研究项目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Transthyretin-related familial amyloid polyneuropathy : Evaluation of CSF enhancement on Serial T1-weighted and FLAIR images following intravenous contrast administration.
转甲状腺素蛋白相关的家族性淀粉样多发性神经病:静脉注射造影剂后串行 T1 加权和 FLAIR 图像上脑脊液增强的评估。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Hirai T;Ando Y;et al.
- 通讯作者:et al.
Measurement of total and differential white blood cell counts in synovial fluid using an automated hematology analyzer.
使用自动血液分析仪测量滑液中的总白细胞计数和差异白细胞计数。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Sugiuchi H;Ando Y;et al.
- 通讯作者:et al.
Analysis and treatment of transthyretin type amyloidosis
运甲状腺素蛋白型淀粉样变性分析及治疗
- DOI:
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:Ando;Y
- 通讯作者:Y
家族性アミロイドーシスの病態と治療
家族性淀粉样变性的病理学和治疗
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Ueda;M;Goto S.;Ando Y.;Ueda M.;Sato T.;Koide-Yoshida S.;Bergstrom J.;Inomata Y.;Yamamoto S.;大林 光念
- 通讯作者:大林 光念
遺伝子検査の実際、2)神経・筋疾患
实际基因检测,2)神经肌肉疾病
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Ueda;M;Goto S.;Ando Y.;Ueda M.;Sato T.;Koide-Yoshida S.;Bergstrom J.;Inomata Y.;Yamamoto S.;大林 光念;植田 光晴
- 通讯作者:植田 光晴
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDO Yukio其他文献
ANDO Yukio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDO Yukio', 18)}}的其他基金
Control of amyloid neuropathy from the aspect of inflammation
从炎症角度控制淀粉样神经病
- 批准号:
15K15195 - 财政年份:2015
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Early diagnosis and analyses of the pathogenesis for amyloidosis with all our previous investigations
通过我们之前的所有研究对淀粉样变性进行早期诊断和发病机制分析
- 批准号:
24249036 - 财政年份:2012
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Analysis of autoantibodies for targeting pathogenesis and therapyof misfolding diseases
靶向错误折叠疾病发病机制和治疗的自身抗体分析
- 批准号:
23659303 - 财政年份:2011
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Hepatocyte replacement therapy for familial amybidotic polyneuropathy combining iPS cells and gene-repair therapy
结合 iPS 细胞和基因修复疗法治疗家族性淀粉样多发性神经病的肝细胞替代疗法
- 批准号:
21390270 - 财政年份:2009
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Why are familial amyloidotic neuropathy patients in Sweden hard to show clinical manifestations.
为什么瑞典的家族性淀粉样神经病患者很难表现出临床表现?
- 批准号:
16406027 - 财政年份:2004
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Gene therapy for familial amybidotic polyneuropathy by urtra-fundaoning artificial nucleic acids
超基人工核酸基因治疗家族性淀粉样多发性神经病
- 批准号:
15390275 - 财政年份:2003
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Gene therapy for familial amyloidotic polyneuropathy (FAP)
家族性淀粉样变性多发性神经病 (FAP) 的基因治疗
- 批准号:
13670655 - 财政年份:2001
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanism of amyloid formation in amyloidosis : Clinical, biochemical, and pathological study
淀粉样变性中淀粉样蛋白形成的机制:临床、生化和病理学研究
- 批准号:
06670660 - 财政年份:1993
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
21st century disease, innovative radiation therapy for amyloidosis
21世纪疾病,淀粉样变性的创新放射疗法
- 批准号:
23K07095 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF OUTCOME TO DISEASE-MODIFYING THERAPY FOR TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY
转甲状腺素蛋白淀粉样变性心肌病疾病缓解治疗结果的决定因素
- 批准号:
495435 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Chip phosphorylation stimulates the degradation of mutant transthyretin to attenuate cardiac amyloidosis
芯片磷酸化刺激突变运甲状腺素蛋白的降解以减轻心脏淀粉样变性
- 批准号:
10905158 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
New Developments in Amyloidosis Research Using Cordyceps Lectin
利用冬虫夏草凝集素研究淀粉样变性的新进展
- 批准号:
23K10950 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a method to differentiate types of cardiac amyloidosis using Raman spectroscopy.
开发一种使用拉曼光谱区分心脏淀粉样变性类型的方法。
- 批准号:
23K17233 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Regulatory mechanism of amyloidosis-like function of seminal vesicle secretory proteins in the acquisition of sperm capacitaion.
精囊分泌蛋白类淀粉样变性功能在精子获能过程中的调节机制。
- 批准号:
23K08748 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Aortic Stenosis and Cardiac Amyloidosis
主动脉瓣狭窄和心脏淀粉样变性
- 批准号:
23K15548 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Amyloidosis Forum: Advancing Drug Development in ATTR Amyloidosis in an Evolving Treatment Landscape.
淀粉样变性论坛:在不断发展的治疗格局中推进 ATTR 淀粉样变性的药物开发。
- 批准号:
10683562 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
腰椎管狭窄标本分析鉴定运甲状腺素蛋白心脏淀粉样变性
- 批准号:
10637491 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别: